Eleven Biotherapeutics Inc. (Nasdaq: EBIO) dosed its first patients in a Phase 3 study of EBI-005 to treat moderate to severe allergic conjunctivitis sending the stock price soaring $1.94 to $4.28.
Eleven Biotherapeutics doses first patients
August 12, 2015 at 14:10 PM EDT
